Biomind Labs Inc (BMND) - Total Liabilities
Based on the latest financial reports, Biomind Labs Inc (BMND) has total liabilities worth CA$1.90 Million CAD (≈ $1.38 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Biomind Labs Inc working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Biomind Labs Inc - Total Liabilities Trend (2021–2025)
This chart illustrates how Biomind Labs Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see BMND total asset value.
Biomind Labs Inc Competitors by Total Liabilities
The table below lists competitors of Biomind Labs Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Orient Paper & Industries Limited
NSE:ORIENTPPR
|
India | Rs7.11 Billion |
|
IFirma SA
WAR:IFI
|
Poland | zł10.94 Million |
|
WT Financial Group Ltd
AU:WTL
|
Australia | AU$26.32 Million |
|
Arribatec Solutions ASA
OL:ARR
|
Norway | Nkr168.17 Million |
|
Ta Jiang Co Ltd
TW:1453
|
Taiwan | NT$1.58 Billion |
|
CHUNGDAHM Learning Inc
KQ:096240
|
Korea | ₩129.42 Billion |
|
Song Ho Industrial Co Ltd
TWO:5016
|
Taiwan | NT$999.69 Million |
|
Acanthe Développement
PA:ACAN
|
France | €21.07 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down Biomind Labs Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Biomind Labs Inc (BMND) net asset quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.00 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.00 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 54346.71 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Biomind Labs Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Biomind Labs Inc (2021–2025)
The table below shows the annual total liabilities of Biomind Labs Inc from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CA$1.74 Million ≈ $1.26 Million |
+29.40% |
| 2024-12-31 | CA$1.34 Million ≈ $970.31K |
-10.95% |
| 2023-12-31 | CA$1.51 Million ≈ $1.09 Million |
+347.35% |
| 2022-12-31 | CA$336.72K ≈ $243.58K |
+0.53% |
| 2021-12-31 | CA$334.95K ≈ $242.30K |
-- |
About Biomind Labs Inc
Biomind Labs Inc., a biotech research and development company, focuses on developing novel pharmaceutical drugs and nanotech delivery systems for various psychiatric and neurological conditions. The company is developing BMND01, which is in Phase II clinical trials for use in the treatment of depression; BMND08, a 5-Metoxi-N,N-dimethyltryptamine sublingual formulation that is in Phase II clinical… Read more